Romark Alinia "approvable" for adults, approval for children
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Romark Labs' Alinia (nitazoxanide) tablet formulation is deemed "approvable" for adult patients 12 years and older Nov. 22. FDA clears the oral suspension for pediatric patients ages one to 11 years on the same day. The new molecular entity is indicated for treatment of diarrhea caused by Cryptosporidium parvum and Giardia lamblia. Alinia is also pending at FDA for use in AIDS patients. Romark says the product will be available in February 200
You may also be interested in...
Romark Alinia Tab. Approval Expected First Half 2004; AIDS Claim To Follow
Romark expects approval in the first half of 2004 for a tablet formulation of its antimicrobial Alinia for use in immunocompetent adults and adolescents with diarrhea associated with Giardia lamblia and Cryptosporidium parvum.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.